Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 477

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Open access
Paiva, Bruno, Vidriales, Maria-Belén, Cerveró, Jorge, Mateo, Gema, Pérez, Jose J., Montalbán, Maria A., Sureda, Anna, Montejano, Laura, Gutiérrez, Norma C., de Coca, Alfonso García, de las Heras, Natalia, Mateos, Maria V., López-Berges, Maria C., García-Boyero, Raimundo, Galende, Josefina, Hernández, Jose, Palomera, Luis, Carrera, Dolores, Martínez, Rafael, de la Rubia, Javier, Martín, Alejandro, Bladé, Joan, Lahuerta, Juan J., Orfao, Alberto, San Miguel, Jesús F.·2008·Blood

Abstract

Minimal residual disease (MRD) assessment is standard in many hematologic malignancies but is considered investigational in multiple myeloma (MM). We report a prospective analysis of the prognostic importance of MRD detection by multiparameter flow cytometry (MFC) in 295 newly diagnosed MM patients uniformly treated in the GEM2000 protocol VBMCP/VBAD induction plus autologous stem cell transplantation [ASCT]). MRD status by MFC was determined at day 100 after ASCT. Progression-free survival (PFS; median 71 vs 37 months, P < .001) and overall survival (OS; median not reached vs 89 months, P = .002) were longer in patients who were MRD negative versus MRD positive at day 100 after ASCT. Similar prognostic differentiation was seen in 147 patients who achieved immunofixation-negative complete response after ASCT. Moreover, MRD− immunofixation-negative (IFx−) patients and MRD− IFx+ patients had significantly longer PFS than MRD+ IFx− patients. Multivariate analysis identified MRD status by MFC at day 100 after ASCT as the most important independent prognostic factor for PFS (HR = 3.64, P = .002) and OS (HR = 2.02, P = .02). Our findings demonstrate the clinical importance of MRD evaluation by MFC, and illustrate the need for further refinement of MM re-sponse criteria. This trial is registered at http://clinicaltrials.gov under identifier NCT00560053.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2008-05-159624

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 477

Metadata

Authors
Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., de las Heras, N., Mateos, M. V., López-Berges, M. C., García-Boyero, R., Galende, J., Hernández, J., Palomera, L., Carrera, D., Martínez, R., de la Rubia, J., Martín, A., Bladé, J., Lahuerta, J. J., Orfao, A., & San Miguel, J. F.
Venue
Blood
Published
2008-11-15
Volume
112
Issue
10
Pages
4017-4023
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2148758597
Cited by
477
References
31
FWCI
14.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2008-05-159624
The paper
Paiva, B., Vidriales, M.-B., Cerveró, J., Mateo, G., Pérez, J. J., Montalbán, M. A., Sureda, A., Montejano, L., Gutiérrez, N. C., de Coca, A. G., de las Heras, N., Mateos, M. V., López-Berges, M. C., García-Boyero, R., Galende, J., Hernández, J., Palomera, L., Carrera, D., Martínez, R., . . . San Miguel, J. F. (2008). Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. https://doi.org/10.1182/blood-2008-05-159624

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.